Next-generation sequencing with a myeloid gene panel in core-binding factor AML showed KIT activation loop and TET2 mutations predictive of outcome
C Y Cher, G M K Leung, C H Au, T L Chan, E S K Ma, J P Y Sim, H Gill, A K W Lie, R Liang, K F Wong, L L P Siu, C S P Tsui, C C So, H W W Wong, S F Yip, H K K Lee, H S Y Liu, J S M Lau, T H Luk, C K Lau, S Y Lin, Y L Kwong and A Y H Leung on behalf of the Hong Kong AML Study Group
Dose-dense and less dose-intense Total Therapy 5 for gene expression profiling-defined high-risk multiple myeloma
Y Jethava, A Mitchell, M Zangari, S Waheed, C Schinke, S Thanendrarajan, J Sawyer, D Alapat, E Tian, C Stein, R Khan, C J Heuck, N Petty, D Avery, D Steward, R Smith, C Bailey, J Epstein, S Yaccoby, A Hoering, J Crowley, G Morgan, B Barlogie and F van Rhee
Randomized phase III trial of consolidation therapy with bortezomib–lenalidomide–Dexamethasone (VRd) vs bortezomib–dexamethasone (Vd) for patients with multiple myeloma who have completed a dexamethasone based induction regimen
S J Jacobus, S V Rajkumar, M Weiss, A K Stewart, E A Stadtmauer, N S Callander, L M Dreosti, M Q Lacy and R Fonseca
You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant).